At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
CLR325 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject and Investigator-blind, Placebo-controlled Study of CLR325 in Chronic Stable Heart Failure Patients
In Brief
A Phase 2 clinical trial evaluating CLR325 and Placebo for Chronic Stable Heart Failure. Completed, enrolled 26 participants across 11 sites in 5 countries.
Detailed Summary
The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Stable Heart Failure
CountriesBelgium, Germany, Netherlands, Singapore, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMay 2016
Primary CompletionJan 2019
TodayJul 2026
First PostedMar 2, 2016
Enrollment StartMay 17, 2016
Primary CompletionJan 14, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.3 years ago
Interventions
CLR325drug
CLR325 Concentrate for solution for infusion
Placeboother
Normal saline